Frontier biological AI models (EDEN) for designing medicines, starting with in vivo cell therapy
Basecamp Research, founded in 2019 by Glen Gowers (CEO) and Oliver Vince, trains frontier biological AI models (EDEN) on the Trillion Gene Atlas, a proprietary genomic dataset gathered through access-and-benefit-sharing partnerships in more than 30 countries. It is applying EDEN to in vivo cell therapy, pairing designed long DNA sequences with large serine recombinases to write them into the genome, and says it has strong preclinical results across multiple modalities. On 2026-09-23 it announced an oversubscribed $140M Series C led by S32; a corrected release on 2026-09-24 changed the named participant from "Anthropic's Anthology Fund" to "Menlo Ventures' Anthology Fund". Reuters reported the round valued the company at $800M; total funding is about $225M. It is headquartered in London with labs in Cambridge, MA, and appointed ex-Biogen executive Richard Pearce as Chief Business Officer.
Drug Discovery📍 London, United KingdomFounded 2019
Current Valuation
$800M
as of 2026-09-23
PRIVATE
QL Price
$800M
0% vs last round
QuantLogix's current estimate for Basecamp Research, published 2026-09-25 — in line with the last disclosed round of $800M (2026-09-23).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$800M
2026-09-23
weight 1
How this price has held up
No round has priced for Basecamp Research since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-25 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Basecamp Research, 2026-09-25 (e99b140d15f7d9c5).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Basecamp Research going public?
No. Basecamp Research is private and has not filed to go public. There is no S-1 on file.
What is Basecamp Research's valuation in 2026?
Basecamp Research is valued at $800M as of 09/23/2026, set by its Series C ($140M, Sep 2026). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Basecamp Research filed an S-1?
No public S-1 is on file for Basecamp Research.
Who are Basecamp Research's investors?
Basecamp Research's investors include S32, Menlo Ventures (Anthology Fund), NVIDIA (NVentures), Singular, Catalio Capital Management, European Tech Collective and 9 more.
How much has Basecamp Research raised?
Basecamp Research has raised $225M in total across 2 disclosed rounds, most recently a Series C of $140M in Sep 2026.
Is Basecamp Research publicly traded — can you buy Basecamp Research stock?
No. Basecamp Research is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Basecamp Research on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
CEO
Glen Gowers
Founded
2019
HQ
London, United Kingdom
Total Raised
$225M
Last Round
Series C — $140M (Sep 2026) · Lead: S32
IPO Status
private
Fundraising Status
Series C · $140M · this month
privateTotal raised $225M2 disclosed rounds
Series C Impact
Round Size
$140M
Primary financing announced
Post-Money Valuation
$800M
Company-announced mark
Round / Post-Money
17.5%
New capital ÷ post-money
Disclosed Funding
$225M
Cumulative disclosed rounds
Step-up compares disclosed post-money valuations. Round / post-money is a financing-size ratio, not an ownership or dilution estimate.
Growth & Valuation
Capital raised per round
Charts built from publicly disclosed funding rounds and revenue estimates. Approximate, not real-time, not investment advice.
Funding History
Round
Amount
Date
Lead Investor
Post-Money
Series C
$140M
Sep 2026
S32
$800M
Series B
$60M
Oct 2024
Singular
—
Vertical Intelligence — Biotech / Gene Therapy
Biotech / Gene Therapy registry data for Basecamp Research has not been collected yet — the weekly vertical sweep hasn't reached this company. Check back soon.
Talent Signal
Hiring data for Basecamp Research has not been collected yet — the monthly talent sweep hasn't reached this company. Check back soon.
Founders & Key People
Glen GowersOliver Vince
Investors
S32 · Menlo Ventures (Anthology Fund) · NVIDIA (NVentures) · Singular · Catalio Capital Management · European Tech Collective · Firebrand River Capital · Inception Fund · King Philanthropies · NATO Innovation Fund · PostScriptum · Redalpine · The Rockefeller Foundation · Sovereign AI · True Ventures
Products
EDEN biological foundation models
Trillion Gene Atlas (proprietary genomic dataset)
In vivo cell therapy pipeline
BiotechAI Drug DiscoveryFoundation ModelsCell TherapyGenomicsUK
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2026-09-23. Refreshed quarterly.